

**Pediatric malignancies**

**Lymphoma**

Hodgkin Lymphoma:

Non-Hodgkin Lymphoma:

Lugano Classification for Hodgkin Lymphoma

Clinical Presentation of Hodgkin Lymphoma:

Clinical manifestation:

**Tumor Lysis Syndrome**

Definition

Etiology

Pathophysiology

Clinical features :

Treatment

**Central Nervous System Tumors:**

Intro

Signs and Symptom

Localizing Signs

Laboratory/Imaging Studies:

Differential Diagnosis:

Treatment

**Retinoblastoma**

2 major forms:

Clinical features:

Diagnosis

Treatment

**Neuroblastoma**

Intro

Clinical features:

Localized Symptoms

Location of metastases

Laboratory/Imaging Studies:

International Neuroblastoma Staging System (INSS)

Treatment

**Wilms Tumor**

Intro

Associated Syndromes:

Clinical




Diagnostics

Staging (NWTS)


**Sarcomas**

Osteosarcoma

Ewing Sarcoma

	Lymphoma	Tumor Lysis Syndrome (TLS)																									
<b>Definition</b>	<ul style="list-style-type: none"> <li>Neoplastic proliferation of lymphoid cells forming a mass.</li> <li>Can arise in a lymph node or in extranodal tissue.</li> </ul>	<ul style="list-style-type: none"> <li>A potentially life-threatening oncologic emergency caused by rapid tumor cell destruction.</li> <li>Massive release of intracellular contents: potassium (K<sup>+</sup>), phosphate (PO<sub>4</sub><sup>3-</sup>), nucleic acids → uric acid.</li> <li>Can lead to renal failure and other serious metabolic complications.</li> </ul>																									
<b>Etiology</b>	<ul style="list-style-type: none"> <li>Third most common cancer among U.S. children ≤14 years old, with an annual incidence of 15 cases per 1 million children.</li> <li>Most common cancer in adolescents 15–19 years old, accounting for over 25% of newly diagnosed cancers.</li> </ul>	<ul style="list-style-type: none"> <li>Most common: after cytotoxic therapy in hematologic malignancies (ALL, AML, NHL).</li> <li>Spontaneous TLS: occurs in patients with very high tumor burden, even before treatment.</li> </ul>																									
<b>Pathophysiology</b>	<ul style="list-style-type: none"> <li><b>Hodgkin Lymphoma (HL)</b></li> <li>1. Classic Hodgkin Lymphoma <ul style="list-style-type: none"> <li>Nodular sclerosing</li> <li>Mixed cellularity</li> <li>Lymphocyte predominant</li> <li>Lymphocyte depleted</li> </ul> </li> <li>2. Nodular Lymphocyte Predominant <ul style="list-style-type: none"> <li>Pathognomonic Feature: Reed-Sternberg (RS) cell. <ul style="list-style-type: none"> <li>Large cell, 15–45 μm in diameter.</li> <li>Multiple or multilobulated nuclei.</li> <li>Hallmark of HL, although similar cells may appear in infectious mononucleosis, non-Hodgkin lymphoma, and other conditions.</li> <li>Clonal origin from germinal center B cells but typically lost most B-cell gene expression and function.</li> </ul> </li> </ul> </li> </ul> 	<ul style="list-style-type: none"> <li><b>Non-Hodgkin Lymphoma (NHL)</b></li> <li>Includes multiple subtypes: <ul style="list-style-type: none"> <li>Burkitt lymphoma</li> <li>Lymphoblastic lymphoma</li> <li>Diffuse large B-cell lymphoma</li> <li>Primary mediastinal B-cell lymphoma</li> <li>Anaplastic large cell lymphoma</li> <li>Other less common types</li> </ul> </li> </ul>	<ol style="list-style-type: none"> <li>Tumor cells lyse → release K<sup>+</sup>, PO<sub>4</sub><sup>3-</sup>, nucleic acids into blood.</li> <li>Nucleic acids → uric acid → hyperuricemia → urate nephropathy → acute kidney injury (AKI).</li> <li>Hyperphosphatemia → PO<sub>4</sub><sup>3-</sup> binds Ca<sup>2+</sup> → calcium phosphate crystals → renal tubule obstruction → AKI.</li> <li>Hypocalcemia secondary to phosphate binding → increased neuronal excitability → risk of seizures.</li> <li>Hyperkalemia → altered resting membrane potential → cardiac arrhythmias.</li> </ol> 																								
<b>Clinical Presentation of Hodgkin Lymphoma:</b>	<ul style="list-style-type: none"> <li>Painless lymphadenopathy.</li> <li>Mediastinal mass (~2/3 of patients).</li> <li>Constitutional symptoms: <ul style="list-style-type: none"> <li>B symptoms (prognostic): <ul style="list-style-type: none"> <li>Weight loss of 10% within 6 months.</li> <li>Drenching night sweats.</li> <li>Unexplained fevers &gt;38°C for 3 consecutive days.</li> </ul> </li> <li>Other symptoms (not prognostic): <ul style="list-style-type: none"> <li>Fatigue, anorexia, mild weight loss.</li> <li>Pain immediately after alcohol consumption.</li> <li>Generalized pruritus, often severe in advanced disease.</li> </ul> </li> </ul> </li> <li>Laboratory findings: <ul style="list-style-type: none"> <li>Markers of inflammation and reticuloendothelial system activation (↑CRP, ESR, ferritin, copper).</li> <li>Anemia of chronic inflammation.</li> </ul> </li> <li>Immune dysregulation: <ul style="list-style-type: none"> <li>Autoimmune neutropenia.</li> <li>Autoimmune hemolytic anemia (AIHA).</li> <li>Immune thrombocytopenia (ITP).</li> <li>Nephrotic syndrome.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Age-specific Notes: <ul style="list-style-type: none"> <li>Non-Hodgkin lymphoma: presentation may vary between 0–14 years and 15–19 years adolescents.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Directly related to electrolyte disturbances and kidney injury.</li> <li>Renal: edema, oliguria, decreased urine output</li> <li>Cardiac: palpitations, arrhythmias, syncope (hyperkalemia)</li> <li>Neuromuscular: tetany, muscle cramps, seizures (hypocalcemia)</li> <li>GI: nausea, vomiting, diarrhea</li> </ul>																								
<b>Clinical Features</b>	<ul style="list-style-type: none"> <li>Very high proliferation rate; early diagnosis and treatment are critical.</li> <li>High risk for tumor lysis syndrome (TLS). <ul style="list-style-type: none"> <li>Can invade CNS and bone marrow.</li> <li>Mediastinal lymphadenopathy may produce cough or shortness of breath.</li> <li>B symptoms (fever, night sweats, weight loss).</li> <li>Burkitt lymphoma may present with abdominal mass or jaw mass, especially in children.</li> </ul> </li> </ul>		<p><b>Table 2.10</b> Criteria for laboratory and clinical diagnosis</p> <table border="1"> <thead> <tr> <th colspan="2">The Cairo–Bishop definition (2004)</th> </tr> </thead> <tbody> <tr> <td>Uric acid</td> <td>≥476 μmol/L (8 mg/dL) or 25% increase</td> </tr> <tr> <td>Potassium</td> <td>≥6.0 mmol/L or 25% increase</td> </tr> <tr> <td>Phosphate</td> <td>≥1.45 mmol/L or 25% increase</td> </tr> <tr> <td>Calcium</td> <td>&lt;1.75 mmol/L or 25% decrease</td> </tr> </tbody> </table> <p>≥2 of these features between 3 days pre- and 7 days post-tumour treatment encompasses the laboratory definition.</p> <p>A clinical diagnosis of TLS can be made if AKI, arrhythmias, or seizures occur in conjunction with the laboratory features.</p> <p>Cairo MS, Bishop M (2004). <i>British Journal of Haematology</i>, 127(1), 3–11.</p>	The Cairo–Bishop definition (2004)		Uric acid	≥476 μmol/L (8 mg/dL) or 25% increase	Potassium	≥6.0 mmol/L or 25% increase	Phosphate	≥1.45 mmol/L or 25% increase	Calcium	<1.75 mmol/L or 25% decrease														
The Cairo–Bishop definition (2004)																											
Uric acid	≥476 μmol/L (8 mg/dL) or 25% increase																										
Potassium	≥6.0 mmol/L or 25% increase																										
Phosphate	≥1.45 mmol/L or 25% increase																										
Calcium	<1.75 mmol/L or 25% decrease																										
<b>Treatment</b>	<ul style="list-style-type: none"> <li>Imaging Examples (for context): <ul style="list-style-type: none"> <li>Anterior mediastinal mass in Hodgkin lymphoma before therapy.</li> <li>PET/CT may show marked FDG uptake and associated neck masses.</li> <li>Post-chemotherapy imaging shows reduction of mediastinal masses.</li> </ul> </li> </ul>		<ol style="list-style-type: none"> <li>IV isotonic fluids: correct electrolytes and maintain urine output</li> <li>Hyperkalemia: cardiac monitoring + IV insulin + dextrose</li> <li>Hyperphosphatemia: hydration, phosphate binders (e.g., sevelamer)</li> <li>Hypocalcemia: usually resolves with phosphate management</li> <li>Hyperuricemia: <ul style="list-style-type: none"> <li>Allopurinol → inhibits uric acid production</li> <li>Rasburicase → converts uric acid → allantoin</li> </ul> </li> <li>Severe cases: urgent hemodialysis if K<sup>+</sup>, phosphate, or uric acid are critically high</li> </ol>																								
<b>Prevention</b>	<table border="1"> <thead> <tr> <th colspan="3">Lugano Classification for Hodgkin Lymphoma</th> </tr> <tr> <th>Stage</th> <th>Involvement</th> <th>Extranodal status</th> </tr> </thead> <tbody> <tr> <td>I</td> <td>- One node or group of adjacent nodes</td> <td>- Single extranodal lesions without nodal involvement</td> </tr> <tr> <td>II</td> <td>- Two or more nodal groups on the same side of the diaphragm</td> <td>- Stage I or II by nodal extent with limited contiguous extranodal involvement</td> </tr> <tr> <td>II bulky</td> <td>- II as above with "bulky" disease</td> <td>- Not applicable</td> </tr> <tr> <td>III</td> <td>- Nodes on both sides of the diaphragm</td> <td>- Not applicable</td> </tr> <tr> <td></td> <td>- Nodes above the diaphragm with spleen involvement</td> <td>- Not applicable</td> </tr> <tr> <td>IV</td> <td>- Additional noncontiguous extralymphatic involvement</td> <td>- Not applicable</td> </tr> </tbody> </table>  <p><b>A:</b> Anterior mediastinal mass in a patient with Hodgkin disease before therapy. <b>B:</b> After 2 mo of chemotherapy</p> <p><b>Hodgkin lymphoma</b> in a young woman <b>ACT</b> shows a homogeneous anterior mediastinal mass (arrows). The arrowhead points to the SVC, A, ascending aorta <b>B, PET/CT</b> in the coronal plane. The mass shows marked FDG activity (arrows). Note the associated left neck mass (arrowhead).</p>	Lugano Classification for Hodgkin Lymphoma			Stage	Involvement	Extranodal status	I	- One node or group of adjacent nodes	- Single extranodal lesions without nodal involvement	II	- Two or more nodal groups on the same side of the diaphragm	- Stage I or II by nodal extent with limited contiguous extranodal involvement	II bulky	- II as above with "bulky" disease	- Not applicable	III	- Nodes on both sides of the diaphragm	- Not applicable		- Nodes above the diaphragm with spleen involvement	- Not applicable	IV	- Additional noncontiguous extralymphatic involvement	- Not applicable		<ul style="list-style-type: none"> <li>Aggressive IV hydration before chemotherapy</li> <li>Medications to prevent hyperuricemia (allopurinol or rasburicase)</li> </ul>
Lugano Classification for Hodgkin Lymphoma																											
Stage	Involvement	Extranodal status																									
I	- One node or group of adjacent nodes	- Single extranodal lesions without nodal involvement																									
II	- Two or more nodal groups on the same side of the diaphragm	- Stage I or II by nodal extent with limited contiguous extranodal involvement																									
II bulky	- II as above with "bulky" disease	- Not applicable																									
III	- Nodes on both sides of the diaphragm	- Not applicable																									
	- Nodes above the diaphragm with spleen involvement	- Not applicable																									
IV	- Additional noncontiguous extralymphatic involvement	- Not applicable																									

	Pediatric Central Nervous System (CNS) Tumors	Retinoblastoma	Pediatric Sarcomas																													
<b>Epidemiology &amp; Etiology</b>	<ul style="list-style-type: none"> <li>Annual incidence: ~47 cases per 1 million children &lt;20 yrs.</li> <li>Highest in infants and children ≤5 yrs: ~52 cases per 1 million; mortality ~30%.</li> <li>Highest morbidity among pediatric malignancies, primarily neurological.</li> <li>Most common solid tumors in children.</li> <li>Mostly primary tumors:               <ul style="list-style-type: none"> <li>Low-grade astrocytomas</li> <li>Embryonic neoplasms: medulloblastoma, ependymoma, germ cell tumors</li> </ul> </li> <li>Etiology often unknown</li> <li>Risk increased with inherited syndromes:               <ul style="list-style-type: none"> <li>Neurofibromatosis types 1 &amp; 2 (NF1, NF2)</li> <li>Li-Fraumeni syndrome</li> <li>von Hippel-Lindau syndrome</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Rare retinal tumor; most present by age 5 years</li> <li>Hereditary (25%): bilateral, multifocal; germline RB1 mutations, median age ~15 months</li> <li>Non-hereditary (majority): unilateral/unifocal; somatic RB1 mutations, median age ~30 months</li> </ul>	<ol style="list-style-type: none"> <li><b>Osteosarcoma (OS)</b> <ul style="list-style-type: none"> <li>Can occur de novo or as a late effect of radiation therapy</li> <li>Associated with Li-Fraumeni syndrome (TP53 mutation)</li> </ul> </li> <li><b>Ewing Sarcoma (ES)</b> <ul style="list-style-type: none"> <li>Primitive neuroectodermal tumor (PNET family)</li> <li>Often affects axial skeleton more than OS</li> <li>Common sites: pelvis, femur, ribs</li> </ul> </li> </ol>																													
<b>Clinical Approach</b>	<ul style="list-style-type: none"> <li>Imaging: MRI brain &amp; spine (study of choice)</li> <li>CSF analysis: histology essential for metastasis</li> <li>LP: contraindicated if increased ICP</li> </ul> <table border="1"> <thead> <tr> <th colspan="2">Signs and Symptoms</th> </tr> <tr> <th>General and Nonlocalizing Symptoms</th> <th>Increased Intracranial Pressure</th> </tr> </thead> <tbody> <tr> <td> <ul style="list-style-type: none"> <li>Headache</li> <li>Vomiting</li> <li>Behavioral changes (listlessness)</li> <li>Developmental delay</li> <li>Weight gain/loss</li> <li>Others: endocrine or autonomic dysfunction, failure to thrive</li> </ul> </td> <td> <ul style="list-style-type: none"> <li>Headache, irritability</li> <li>lethargy and vomiting</li> <li>Bulging fontanelle/separation of sutures</li> <li>Papilledema</li> <li><b>Parinaud syndrome, upward gaze palsy</b></li> <li>Others: anisocoria (unequal pupil size), ataxia, head tilt</li> </ul> </td> </tr> <tr> <th colspan="2">Localizing Signs</th> </tr> <tr> <th>Anatomic Location</th> <th>Common signs and symptoms</th> </tr> <tr> <td><b>1. Frontal lobe</b></td> <td>- Personality changes, decreased speech (Broca's), seizures.</td> </tr> <tr> <td><b>2. Temporal lobe</b></td> <td>- Seizures, poor memory, language comprehension (Wernicke's).</td> </tr> <tr> <td><b>3. Parietal lobe</b></td> <td>- Decreased sense of touch, pain, poor spatial and visual perception, poor interpretation of language</td> </tr> <tr> <td><b>4. Occipital lobe</b></td> <td>- Poor or Loss of Vision.</td> </tr> <tr> <td><b>5. Cerebellum</b></td> <td>- Ataxia, muscle movement, posture.</td> </tr> <tr> <td><b>6. Brain stem</b></td> <td>- Weakness, cranial neuropathies (III-XII), autonomic fxn.</td> </tr> <tr> <td><b>7. Thalamus</b></td> <td>- Weakness/motor control, consciousness, sleep/wake cycle</td> </tr> <tr> <td><b>8. Hypothalamus</b></td> <td>- Autonomic function as temp regulation, thirst, hunger.</td> </tr> <tr> <td></td> <td>- Endocrinopathies</td> </tr> </tbody> </table>	Signs and Symptoms		General and Nonlocalizing Symptoms	Increased Intracranial Pressure	<ul style="list-style-type: none"> <li>Headache</li> <li>Vomiting</li> <li>Behavioral changes (listlessness)</li> <li>Developmental delay</li> <li>Weight gain/loss</li> <li>Others: endocrine or autonomic dysfunction, failure to thrive</li> </ul>	<ul style="list-style-type: none"> <li>Headache, irritability</li> <li>lethargy and vomiting</li> <li>Bulging fontanelle/separation of sutures</li> <li>Papilledema</li> <li><b>Parinaud syndrome, upward gaze palsy</b></li> <li>Others: anisocoria (unequal pupil size), ataxia, head tilt</li> </ul>	Localizing Signs		Anatomic Location	Common signs and symptoms	<b>1. Frontal lobe</b>	- Personality changes, decreased speech (Broca's), seizures.	<b>2. Temporal lobe</b>	- Seizures, poor memory, language comprehension (Wernicke's).	<b>3. Parietal lobe</b>	- Decreased sense of touch, pain, poor spatial and visual perception, poor interpretation of language	<b>4. Occipital lobe</b>	- Poor or Loss of Vision.	<b>5. Cerebellum</b>	- Ataxia, muscle movement, posture.	<b>6. Brain stem</b>	- Weakness, cranial neuropathies (III-XII), autonomic fxn.	<b>7. Thalamus</b>	- Weakness/motor control, consciousness, sleep/wake cycle	<b>8. Hypothalamus</b>	- Autonomic function as temp regulation, thirst, hunger.		- Endocrinopathies	<ul style="list-style-type: none"> <li>Leukocoria (most common presenting sign)</li> <li>Strabismus</li> <li>Painful, red eye</li> <li>Loss of vision</li> <li>Retinal detachment (later stages)</li> <li>Rare: orbital cellulitis, nystagmus, proptosis</li> <li>Metastasis: bone, bone marrow, liver, CNS</li> </ul>	<ul style="list-style-type: none"> <li>Pain and mass at the primary site</li> <li>Typically involves metaphysis of long bones</li> <li>Most common sites: distal femur &gt; proximal tibia &gt; proximal humerus</li> <li>Spread:           <ul style="list-style-type: none"> <li>Skip lesions</li> <li>Hematogenous → lungs and other bones</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Local pain and mass</li> <li>Systemic symptoms: fever, weight loss</li> <li>Metastasis: lungs, bone, bone marrow</li> </ul>
Signs and Symptoms																																
General and Nonlocalizing Symptoms	Increased Intracranial Pressure																															
<ul style="list-style-type: none"> <li>Headache</li> <li>Vomiting</li> <li>Behavioral changes (listlessness)</li> <li>Developmental delay</li> <li>Weight gain/loss</li> <li>Others: endocrine or autonomic dysfunction, failure to thrive</li> </ul>	<ul style="list-style-type: none"> <li>Headache, irritability</li> <li>lethargy and vomiting</li> <li>Bulging fontanelle/separation of sutures</li> <li>Papilledema</li> <li><b>Parinaud syndrome, upward gaze palsy</b></li> <li>Others: anisocoria (unequal pupil size), ataxia, head tilt</li> </ul>																															
Localizing Signs																																
Anatomic Location	Common signs and symptoms																															
<b>1. Frontal lobe</b>	- Personality changes, decreased speech (Broca's), seizures.																															
<b>2. Temporal lobe</b>	- Seizures, poor memory, language comprehension (Wernicke's).																															
<b>3. Parietal lobe</b>	- Decreased sense of touch, pain, poor spatial and visual perception, poor interpretation of language																															
<b>4. Occipital lobe</b>	- Poor or Loss of Vision.																															
<b>5. Cerebellum</b>	- Ataxia, muscle movement, posture.																															
<b>6. Brain stem</b>	- Weakness, cranial neuropathies (III-XII), autonomic fxn.																															
<b>7. Thalamus</b>	- Weakness/motor control, consciousness, sleep/wake cycle																															
<b>8. Hypothalamus</b>	- Autonomic function as temp regulation, thirst, hunger.																															
	- Endocrinopathies																															
<b>Differential Diagnosis</b>	<ul style="list-style-type: none"> <li>Malignant, metastatic, or benign tumors</li> <li>AV malformation, aneurysm</li> <li>Brain abscess, intracranial hemorrhage</li> <li>Pseudotumor cerebri</li> <li>Vasculitis</li> </ul>	<ul style="list-style-type: none"> <li>Examination under anesthesia for tumor visualization and intraocular pressure</li> <li>Imaging: ocular ultrasound, orbit &amp; brain MRI, bone scan, bone marrow studies</li> <li>Avoid CT scan: radiation risk in RB1 mutation</li> <li>Biopsy contraindicated: risk of tumor seeding</li> </ul>	<ul style="list-style-type: none"> <li>Plain X-ray: osteoblastic, osteolytic, or mixed           <ul style="list-style-type: none"> <li>Classical signs: Codman triangle (periosteal elevation), sunburst pattern (tumor extension through periosteum)</li> </ul> </li> <li>Chest CT: rule out pulmonary metastasis</li> <li>Biopsy: confirm diagnosis</li> </ul>	<ul style="list-style-type: none"> <li>Bilateral bone marrow biopsies: detect marrow metastases</li> <li>Plain X-ray:           <ul style="list-style-type: none"> <li>Characteristic onion skin appearance</li> <li>Can also show Codman triangle or sunburst pattern</li> </ul> </li> </ul>																												
<b>Treatment</b>	<ul style="list-style-type: none"> <li>Multimodal: surgery, chemotherapy, radiation</li> <li>Surgery: complete excision or maximal debulking</li> <li>Dexamethasone: high-dose for tumor-associated edema</li> <li>5-year overall survival: ~50-60%</li> </ul>	<ul style="list-style-type: none"> <li>Surgery, chemotherapy, radiation, laser photocoagulation</li> <li>Note: Leukocoria = white reflex in pupil instead of normal red reflex.</li> </ul>	<ul style="list-style-type: none"> <li>Surgery + chemotherapy</li> <li>Radiation therapy: NOT used</li> </ul>	<ul style="list-style-type: none"> <li>Surgery + chemotherapy + radiation</li> </ul>																												
	<p>Tumor Location (NCI SEER Data)</p> <ul style="list-style-type: none"> <li>Infratentorial tumor location (43.2%)           <ul style="list-style-type: none"> <li>Supratentorial region (40.9%)</li> <li>Spinal cord (4.9%)</li> <li>Multiple sites (11%).</li> </ul> </li> <li>Infratentorial: Make up the majority of pediatric brain tumor           <ul style="list-style-type: none"> <li>Most common malignant: medulloblastoma (originate from embryonic stem cells)</li> </ul> </li> <li>Supratentorial:           <ul style="list-style-type: none"> <li>Most common is craniopharyngioma, remnant of Rathke's pouch of anterior pituitary gland.</li> </ul> </li> </ul>	<ol style="list-style-type: none"> <li>Soft tissue sarcomas           <ul style="list-style-type: none"> <li>Most common: Rhabdomyosarcoma</li> </ul> </li> <li>Bone sarcomas           <ul style="list-style-type: none"> <li>Osteosarcoma (OS)</li> <li>Ewing Sarcoma (ES)</li> </ul> </li> </ol>																														



### Comparison of Features of Osteosarcoma and the Ewing Family tumor

FEATURE	OSTEOSARCOMA	EWING FAMILY OF TUMORS
Age	2nd decade	2nd decade
Race	All races	Primarily whites
Sex (M:F)	1.5 : 1	1.5 : 1
Predisposition	Retinoblastoma, Li-Fraumeni syndrome, Paget disease, radiotherapy	None known
Site	Metaphyses of long bones	Diaphyses of long bones, flat bones
Presentation	Local pain and swelling; often history of injury	Local pain and swelling; fever
Radiographic findings	Sclerotic destruction (less often lytic); sunburst pattern	Primarily lytic, multilaminar periosteal reaction ("onion-skinning")
Differential diagnosis	Ewing sarcoma, osteomyelitis	Osteomyelitis, eosinophilic granuloma, lymphoma, neuroblastoma, rhabdomyosarcoma
Metastasis	Lungs, bones	Lungs, bones
Treatment	Chemotherapy Ablative surgery of primary tumor	Chemotherapy Radiotherapy and/or surgery of primary tumor
Outcome	Without metastases, 70% cured; with metastases at diagnosis, <20% survival	Without metastases, 65-75% cured; with metastases at diagnosis, 20-30% survival

	Neuroblastoma	Wilms Tumor (Nephroblastoma)
• Definition:	<ul style="list-style-type: none"> <li>Embryonal malignancy.</li> <li>Malignant neuroendocrine tumor of the sympathetic nervous system.</li> <li>Originates from neural crest cells and may secrete catecholamines.</li> </ul>	<ul style="list-style-type: none"> <li>Most common primary malignant renal tumor in childhood.</li> <li>Second most common malignant abdominal tumor after neuroblastoma.</li> <li>Pathology: Arises from primitive metanephric blastema (precursor of normal kidney).</li> </ul>
• Epidemiology	<ul style="list-style-type: none"> <li>Most common malignancy in infancy.</li> <li>Fourth most common childhood malignancy.</li> <li>Median age: 22 months (mostly &lt;5 years).</li> <li>Most common extracranial solid tumor of childhood (8–10%).</li> </ul>	<ul style="list-style-type: none"> <li>Mean age: 3–3.5 years.</li> <li>Mostly unilateral; up to 10% bilateral.</li> <li>Median age unilateral: 44 months.</li> <li>Median age bilateral: 31 months.</li> </ul>
• Location	<ul style="list-style-type: none"> <li>Adrenal glands: 45%</li> <li>Retroposterior sympathetic ganglia: 25%</li> <li>Paravertebral chest ganglia: 15%</li> <li>Neck: 5%</li> <li>Pelvic sympathetic tissue: 5%</li> <li>Can occur wherever sympathetic nervous tissue exists.</li> </ul>	<ul style="list-style-type: none"> <li>Etiology: <ul style="list-style-type: none"> <li>Exact cause unknown.</li> <li>Associated with genetic syndromes and mutations.</li> </ul> </li> </ul>
• Clinical Features:	<ul style="list-style-type: none"> <li>General Symptoms: Failure to thrive, weight loss, fever, nausea, vomiting, loss of appetite, hypertension.</li> <li>Local Symptoms: Abdominal supraprenal mass (classic presentation), chest or neck mass depending on site.</li> <li>Paraneoplastic Effects: Vasodilative intestinal peptide (VIP) secretion, opsochomus-myoclonus syndrome.</li> <li>Metastatic Symptoms: Bone pain, anemia (bone marrow involvement), subcutaneous nodules, periorbital ecchymoses ("raccoon eyes").</li> </ul>	<ul style="list-style-type: none"> <li>Palpable abdominal mass: smooth, non-tender, unilateral, does not cross midline.</li> <li>Other symptoms: abdominal pain (20–40%), fever, hypertension, hematuria.</li> <li>Most common presentation: incidentally discovered by parents.</li> </ul>

Localized Symptoms	
Location of primary tumors	Associated signs and symptoms
Abdomen	<ul style="list-style-type: none"> <li>Palpable, firm, irregular abdominal mass that may cross the midline, in contrast to nephroblastoma, which is smooth and usually does not cross the midline.</li> <li>Abdominal distension and pain, Hepatomegaly, Constipation</li> </ul>
Chest (paravertebral ganglia)	<ul style="list-style-type: none"> <li>Spinal cord compression: back pain, weakness, numbness, ataxia, loss of bowel or bladder control.</li> <li>Dyspnea, cough, Inspiratory stridor.</li> </ul>
Neck	<ul style="list-style-type: none"> <li>Horner syndrome, if the stellate ganglion is involved</li> <li>Symptoms due to spinal cord compressions.</li> </ul>

Location of metastases	
Location	Associated signs and symptoms
Skin	- Subcutaneous nodules
Bones	- Bone pain - Anemia (bone marrow suppression)
Orbit of the eye	- Periorbital ecchymoses (raccoon eyes), Proptosis.



Raccoon eyes




- A left supra-renal mass with typical stippled calcifications (arrow in A) and a mass with calcifications (arrow in B) displacing the left kidney inferiorly.

• Laboratory and Imaging Studies:	<ul style="list-style-type: none"> <li>CBC and X-ray (calcifications may be present).</li> <li>Urinary catecholamines (VMA, HVA) elevated in ~90%.</li> <li>CT scan: chest, abdomen, pelvis; may show calcification and hemorrhage.</li> <li>MIBG scan for localization and metastasis.</li> <li>Bilateral bone marrow aspiration and biopsy for marrow involvement.</li> <li>Tissue biopsy required for definitive diagnosis.</li> </ul>	<ul style="list-style-type: none"> <li>History: pre-existing conditions, family history of cancer or congenital defects.</li> <li>Physical Examination: BP, weight, height, abdominal masses, congenital anomalies.</li> <li>Laboratory Workup: CBC, platelets, urine analysis, kidney and liver function tests, electrolytes.</li> <li>Imaging Studies: <ul style="list-style-type: none"> <li>Ultrasound: evaluates necrosis, hemorrhage, hydronephrosis, differentiates solid vs cystic masses.</li> <li>Doppler US: evaluates collecting system, detects tumor thrombi in renal veins/IVC.</li> <li>CT scan: defines tumor extent, contralateral kidney, metastasis; chest CT screens pulmonary metastasis.</li> <li>MRI: used if extensive tumor thrombus or differentiation from nephrogenic rests is needed.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Rounded solid appearing mass is seen in the inferior region of the right kidney.</li> <li>The mass shows no obvious calcifications.</li> <li>IVC thrombus in a child with Wilms' tumor. Longitudinal sonogram of the IVC shows extrinsic tumor thrombus (arrow) filling and expanding the IVC lumen and extending into the right atrium (RA).</li> <li>CT is useful to define the extent of disease, integrity of contralateral kidney and metastasis.</li> <li>Chest CT to screen for pulmonary metastasis.</li> </ul>
• Treatment	<ul style="list-style-type: none"> <li>Determined by patient age and clinical stage.</li> <li>Spontaneous remission possible even in metastatic disease.</li> </ul>	<ul style="list-style-type: none"> <li>Stage-dependent.</li> <li>Neoadjuvant chemotherapy → nephrectomy → adjuvant chemotherapy.</li> </ul>	

International Neuroblastoma Staging System (INSS)	
Stage	Definition
1	<ul style="list-style-type: none"> <li>Localized tumor</li> <li>Complete gross excision with or without microscopic residuals</li> <li>Negative ipsilateral lymph nodes</li> </ul>
2A	<ul style="list-style-type: none"> <li>Localized tumor</li> <li>Incomplete gross excision</li> <li>Negative ipsilateral lymph nodes</li> </ul>
2B	<ul style="list-style-type: none"> <li>Localized tumor</li> <li>Complete or incomplete gross excision</li> <li>Positive ipsilateral lymph nodes</li> </ul>
3	<ul style="list-style-type: none"> <li>Unresectable unilateral tumor that crosses the midline with or without lymph node involvement</li> <li>Any tumor with positive contralateral lymph nodes</li> <li>Midline tumor with bilateral tumor or lymph node involvement</li> </ul>
4	<ul style="list-style-type: none"> <li>Any tumor with dissemination to distant lymph nodes or other organs (bone, liver, skin), with the exception of Stage 4S disease</li> </ul>
4s	<ul style="list-style-type: none"> <li>Localized primary tumor with dissemination to skin, liver, or bone marrow, occurring in infants &lt; 12 months</li> </ul>

National Wilms Tumor Study (NWTs) staging	
Stage	Definition
Stage I	- Tumor confined to the kidney & completely excised
Stage II	<ul style="list-style-type: none"> <li>Tumor outside the kidney but completely excised</li> <li>Local tumor spillage during surgery</li> <li>Lymph nodes negative</li> </ul>
Stage III	<ul style="list-style-type: none"> <li>Non hematogenous disease confined to the abdomen</li> <li>Perioperative rupture of renal capsule</li> <li>Diffuse tumor spillage during surgery</li> <li>Peritoneal implants</li> <li>Positive lymph nodes</li> </ul>
Stage IV	- Hematogenous metastases to lungs or liver
Stage V	- Bilateral Wilms' tumor




Differential Diagnosis of Abdominal and Pelvic Tumors in Children			
Tumor	Age	Clinical signs	Laboratory finding
Wilms tumor	Preschool	- Unilateral flank mass, aniridia, hemihypertrophy	- Hematuria, polycythemia, thrombocytosis, elevated PTT
Neuroblastoma	Preschool	- GIT and GUT obstruction, raccoon eyes, myoclonus-opsoclonus, diarrhea, skin nodules	- Increased urinary vanillylmandelic acid, homovanillic acid, or ferritin - Stippled calcification in the mass
Non-Hodgkin lymphoma	>1 yr	- Intussusception in >2 Yo	- Increased lactate dehydrogenase - Blood cytopenia caused by bone marrow involvement

Differential Diagnosis of Abdominal and Pelvic Tumors in Children			
Tumor	Age	Clinical signs	Laboratory finding
Rhabdomyosarcoma	All	- GIT and GUT obstruction - Abdominal pain, vaginal bleeding, paratesticular mass	- Hypercalcemia, blood cytopenia caused by bone marrow involvement
Germ cell tumor/teratoma	Preschool, teenage	- Females: Abdominal pain, vaginal bleeding - Males: Testicular mass, new-onset hydrocele, sacrococcygeal mass/dimple	- Increased $\beta$ -human chorionic gonadotropin, increased $\alpha$ -fetoprotein
Hepatoblastoma	Birth-3 yr	- RUQ mass, jaundice - Early puberty in males	- Increased $\alpha$ -fetoprotein
Hepatocellular carcinoma	School age	- RUQ mass, jaundice - Hepatitis B, cirrhosis	- Increased $\alpha$ -fetoprotein

	Wilms Tumor	Neuroblastoma
Abdominal mass	- yes	- yes
Primary origin	- intrarenal	- Extrarenal, from adrenal gland or paravertebral sympathetic ganglia
Physical examination	- Displacing mass, mainly confined to the flank	- Non-mobile mass, more likely to cross the midline
Pattern of spread	- Direct expansion with displacement of adjacent structures	- Encasement of vessels and aortic elevation
Other	- Intrinsically displaces urinary collecting systems, Asymptomatic, marcoglossia, HTN, hematuria	- Externally displaces kidney, Neural extension, Often calcified, Irritable child, tender, Raccoon eyes

\* neuroblastoma (mc in infancy)  
(Neuroendocrine) \$ in child  
mc extracranial solid)  
↳ 22 months



cross Abd

⇒ indes ⇒ CBC + x-ray = calcification  
⇒ CT all  
febb) ⇒ urine catecholamines (UMA, HVA)

معدن ستن لک

Very med  
A

44 m